UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Earning passive income online is more accessible than ever. Discover effective strategies to start your online income journey.
15,272 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
In 2022, the S&P 500 plunged while a healthcare-focused ETF held its ground better than most. This story examines why...
IonQ stands at the crossroads of hype and real-world adoption in quantum computing. This ionq stock analysis: sell pi...
A prominent money advisor challenges the traditional retirement bucket approach, proposing a simple one-year cash cus...
Gas costs are lifting travel bills for Memorial Day weekend, with households facing higher pump prices and investors ...
A high-profile finale featuring Paul McCartney highlighted the financial calculus networks face as linear TV ad spend...
Markets react to renewed talks on extending an Iran ceasefire, with potential sanctions relief and Oil-flow changes o...
A CEO’s drastic HR purge and a high-profile EEOC lawsuit against The New York Times collide at a moment of market vol...
As earnings season arrives, smart investors are drilling into Transcat's 2026 earnings outlook. This guide breaks dow...
A rare Super El Niño could intensify Asia's energy crunch, threatening households and factories already squeezed by h...
LadderUp Housing secures a multi-year investment from the Richard King Mellon Foundation to broaden its rent-to-homeo...
Park Aerospace appears set for a pivotal 2026, with a stronger backlog and disciplined cost management. This analysis...